A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol
Acta Obstetricia et Gynecologica Scandinavica · 2026-04 · 105 (4) · 568-574
DOI: 10.1111/aogs.70182 ↗At a glance
Journal article in Acta Obstetricia et Gynecologica Scandinavica, published online on 2026-03-07. Written by Herjan J T Coelingh Bennink and 9 co-authors. Institution: Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Contraceptives, Oral, Combined, Estetrol, Gonadotropin-Releasing Hormone, Perimenopause. Cited 3 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
The introduction of oral GnRH antagonists has created the possibility to replace progestins in combined oral contraceptives as the suppressor of ovarian function. A concept for this new approach to oral hormonal contraception is the combination of 40 mg relugolix, known to inhibit ovulation, and a low dose of the fetal estrogen estetrol. Major noncontraceptive benefits of this regimen will be the establishment of continuous amenorrhea and a smooth and symptomless perimenopausal transition to the postmenopausal status, creating a life cycle endocrine management approach for women (the RE4Women concept). An additional long‐term effect of RE4W is the expected strong reduction of the incidence of breast cancer due to the absence of luteal progesterone and progestins. The dose of estetrol maintaining estrogen function, preventing perimenopausal symptoms, and not causing unacceptable endometrial growth and/or breakthrough bleeding will be assessed in two Phase 2 studies in women aged 18–35 and 36–51 years, respectively.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- Pandora Endocrine Innovation, Bergen, The Netherlands.
- University College Hospital, NHS Foundation Trust, London, UK.
- Department of Obstetrics and Gynaecology, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
- Department of Obstetrics and Gynecology, University of Verona, Verona, Italy.
- Specialty of Obstetrics, Gynaecology and Neonatology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
ORCID profiles: Herjan J T Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L Westhoff, Kristina Gemzell-Danielsson
Cite
APA
Coelingh Bennink, H. J. T., Afors, K., Bahamondes, L., Graziottin, A., Bateson, D., Bombas, T., Osuga, Y., Palacios, S., Westhoff, C. L., & Gemzell-Danielsson, K. (2026). A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol. Acta Obstetricia et Gynecologica Scandinavica, 105(4), 568-574. https://doi.org/10.1111/aogs.70182
Vancouver
Coelingh Bennink HJT, Afors K, Bahamondes L, Graziottin A, Bateson D, Bombas T, et al. A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(4):568-574. doi:10.1111/aogs.70182
BibTeX
@article{CoelinghBennink2026,
author = {Coelingh Bennink, Herjan J T and Afors, Karolina and Bahamondes, Luis and Graziottin, Alessandra and Bateson, Deborah and Bombas, Teresa and Osuga, Yutaki and Palacios, Santiago and Westhoff, Carolyn L and Gemzell-Danielsson, Kristina},
title = {A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
volume = {105},
number = {4},
pages = {568--574},
doi = {10.1111/aogs.70182}
}
EUVIMED